Orphan Reach recognises the importance of emerging regions such as Asia Pacific for the conduct of clinical trials. With its huge population and wide spectrum of diseases, India can provide considerable advantages:

  • Extensive population
  • Wide variety of diseases including many rare and ultra-rare diseases
  • Developed medical practices
  • English as official language used in medical records, hospital administration and regulatory administration
  • Cost efficiencies associated with resources leading to lower development costs
  • Experienced investigators and clinicians (many trained in the West)
  • Rapid enrolment leading to lower development costs
  • Fast regulatory timelines and simplified regulatory process
  • Exemption in excise duty and service tax on clinical research services offers a further financial incentive
  • Quality and GCP guidelines compatible with international requirements
  • Huge work-force availability (from qualified young professionals)
  • Major treatment-naïve patient populations

    • Why not visit India with Orphan Reach?